health
Cancer jab can eradicate entire tumours in patients, trial shows
Jab brought ‘unprecedentedly strong responses’ in patients whose disease had become resistant to chemotherapy and immunotherapy
TL;DR
- Amivantamab, a triple-action cancer jab, has shown unprecedented results in an international trial, eradicating tumours in 15 patients and shrinking them in over a third.
- The trial involved 102 patients with advanced head and neck cancer whose disease had become resistant to other treatments.
- Amivantamab works by blocking EGFR and MET pathways and activating the immune system to attack tumours.
- The jab is administered subcutaneously, making it quicker and more convenient for patients compared to intravenous treatments.
- Patients like Carl Walsh experienced significant improvement in quality of life, with reduced swelling, pain, and a return to a normal diet and speech.
- Researchers highlighted the significance of the results in patients with HPV-negative head and neck cancers, which are typically harder to treat.
- Amivantamab is also being evaluated in clinical trials for lung, colorectal, brain, and gastric cancers.